Definium Therapeutics, Inc.

As of June 30, 2026, Definium Therapeutics, Inc. carries a market capitalization of 5.48B, placing it among publicly traded companies globally. Its enterprise value stands at 4.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Definium Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Definium Therapeutics, Inc. has 132.74M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Definium Therapeutics, Inc. maintains a current ratio of 6.95, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.97, indicating elevated leverage, while an interest coverage ratio of -45.33 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Definium Therapeutics, Inc. posted a negative return on equity (ROE) of -64.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -51.35, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 98.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Definium Therapeutics, Inc. generated - - in revenue and converted that into -309.67M in net income, yielding earnings per share of -3.06. EBITDA reached -199.17M, while operating income came in at -199.17M.

As of June 30, 2026, Definium Therapeutics, Inc. holds 948.72M in cash and equivalents against 31.92M in total debt, resulting in a net debt position of -541.64M. Total book value stands at 804.12M, with working capital of 818.32M providing operational flexibility.

Definium Therapeutics, Inc. produced -147.01M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.52: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.19, meaning Definium Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Definium Therapeutics, Inc.'s most recent stock split took place on August 29, 2022 with a 15:1 split ratio.

As of June 30, 2026, Definium Therapeutics, Inc. has an Altman Z-Score of 18.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.